Generic Name
Clidinium bromide and Chlordiazepoxide

Trade Name
Epirax

Manufacturer
Eipico-manufacturer

Risk Category
D* Positive evidence of human fetal risk exists. Potential benefits may warrant use of the drug in pregnant women despite potential risks (e.g. life threatening situations or serious illness). The risk category is C for Clidinium.

FDA Pregnancy Risk Categories

Place (not click) your mouse cursor over the bold words in the text below to receive description

Indication
Parasympatholytic. Sedative for treatment of dyspepsia.

Fetal Risk

Use of parasympatholytic agents in general has been reported to cause minor malformations in 1st trimester. No data for clidinium. No adequate human data for chlordiazepoxide but suggested possible association with increased risk of malformations (microcephaly, duodenal atresia, meckels diverticulum and deafness), growth and mental retardation, increased fetal death rate. Chronic maternal ingestion of the drug can cause neonatal withdrawal. If used in labor it causes hypotonia, hypothermia and poor feeding in the newborns.

Breast Feeding
No data available for chlordiazepoxide, should be avoided No data for clidinium.

Other Trade Names
Poxidium Bralix Librax Epirax

The information on this Web site is not intended as a substitute for the advice and care of your doctor or other health-care provider. Always consult your doctor if you have any questions about exposures during pregnancy and lactation, and before you take any medications. Please read the Terms and Conditions before using this website.